香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pa Shun International Holdings Limited 百信國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：574） 截 至2021年12月31日止年度之全年業績公佈 茲 提 述 百 信 國 際 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）日 期 為2022年3月31日內容有關截至2021年12月31日止年度之未經審核全年業績的 公 佈（「未經審核業績公佈」）及 本 公 司 日 期 為2022年3月28日、2022年4月21日、 2022年5月12日、2022年6月24日、2022年7月21日、2022年10月27日、2022年11月 29日、2023年1月30日、2023年3月14日、2023年4月21日、2023年4月28日、2023年 5月5日、2023年5月29日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 1 Pa Shun International Holdings Limited 百信國際控股有限公司 （於開曼群島註冊成立的有限公 司） （股份代 號：574） 截至2021年12月31日止年度之未經審核全年業績公佈 未經審核綜合全年業績 由於下文「延遲刊發截至2021年12月31日止年度之經審核全年業績及寄發截至2021 年12月31日止年度之年報」一段所述原因，百信國際控股有限公司（「本公司」）及其 附屬公司（統稱「本集團」）全年業績的審計程序本公佈日期尚未完成。本公司之董事 （「董事」）會（「董事會」）宣佈本集團截至2021年12月31日止年度之未經審核綜合業 績，連同截至2020年12月31日止年度之比較經審核數字如下： 綜合損益表 截至2021年12月31日止年度 | --- | --- | --- | --- | |------------------------------|------ ...

Financial Performance - Total revenue for the year ended December 31, 2020, was RMB 474.835 million, a decrease of 43.8% compared to RMB 845.448 million in 2019[9]. - Gross profit for 2020 was RMB 17.697 million, down 57.8% from RMB 41.932 million in the previous year[9]. - The company reported a net loss of RMB 419.189 million for 2020, which is a 116.7% increase in loss compared to RMB 193.399 million in 2019[9]. - Loss attributable to equity holders of the company was RMB 418.454 million, an increase of 116.0% from RMB 193.721 million in the prior year[9]. - Basic loss per share for 2020 was RMB 28.37, compared to RMB 13.38 in 2019, reflecting a 112.0% increase in loss per share[9]. - The company did not recommend the payment of any final dividend for the year ended December 31, 2020[9]. - The company recorded a net loss of RMB 419.2 million for the year, an increase of approximately 116.7% from RMB 193.4 million in the previous year[20]. - The group reported a loss of approximately RMB 419.19 million for the year ended December 31, 2020, compared to a loss of RMB 193.40 million for the previous year[176]. Assets and Liabilities - Non-current assets as of December 31, 2020, were RMB 305.093 million, a decrease from RMB 331.995 million in 2019[10]. - Current liabilities increased to RMB 200.259 million in 2020 from RMB 153.974 million in 2019[10]. - Total assets less current liabilities amounted to RMB 302.926 million in 2020, down from RMB 771.892 million in 2019[10]. - The company’s total equity as of December 31, 2020, was RMB 277.982 million, a significant decrease from RMB 683.582 million in 2019[10]. - As of December 31, 2020, cash and cash equivalents totaled RMB 15.3 million, down from RMB 26.0 million a year earlier[21]. - The current ratio as of December 31, 2020, was 0.99, a significant decrease from 3.86 on December 31, 2019, due to reclassification of bonds to current liabilities[21]. - As of December 31, 2020, the company's net current liabilities amounted to approximately RMB 2.17 million, indicating significant uncertainty regarding the company's ability to continue as a going concern[74]. Operational Challenges - Gross profit decreased by approximately 57.8% to RMB 17.7 million, with a gross margin decline from 5.0% to 3.7% due to intensified competition in pharmaceutical distribution[14]. - Other income and gains fell by approximately 23.8% to RMB 17.0 million, primarily due to a decrease in royalty income from RMB 8.2 million to RMB 3.4 million[17]. - Net other losses increased by approximately 110.1% to RMB 414.6 million, largely due to expected impairment losses on overdue receivables of RMB 305.3 million[18]. - Loss before tax increased by approximately 123.5% to RMB 425.8 million, driven by higher net other losses and reduced gross profit[18]. - The company faced significant operational challenges, leading to a substantial increase in net loss year-over-year[200]. Corporate Governance - The board consists of three executive directors, three non-executive directors, and three independent non-executive directors, ensuring strong independence[45]. - The audit committee includes three independent non-executive directors, ensuring oversight and compliance with financial regulations[53]. - The company has established appropriate insurance arrangements for directors and senior management against potential legal actions[48]. - Continuous professional development programs are encouraged for all directors to enhance their knowledge and skills[48]. - The company has faced a situation of non-compliance with corporate governance codes due to the resignation of independent directors, affecting the minimum required number[51]. - The chairman and CEO roles were held by Mr. Chen Yanfei until June 17, 2020, which deviated from corporate governance codes[49]. - The Corporate Governance Committee reviewed and monitored the company's compliance with legal and regulatory requirements, with no significant violations reported for the year ending December 31, 2020[63]. Risk Management - The board of directors is responsible for establishing and maintaining effective risk management and internal control systems, which were reviewed and deemed effective for the year ended December 31, 2020[75]. - The company has adopted a comprehensive risk management process that includes risk identification, assessment, valuation, and handling[76]. - The company faces various financial risks, including foreign exchange, interest rate, credit, liquidity, and price risks[116]. - The company is considering various alternatives to secure additional funding, including obtaining new long-term debt through pledging property development project assets[74]. Market and Industry Conditions - The company operates primarily in three business segments in China: pharmaceutical distribution, self-operated retail pharmacies, and pharmaceutical manufacturing[107]. - The company faces significant business risks due to the slowing economic growth in China, particularly in the southwest region[110]. - Regulatory changes in the Chinese pharmaceutical industry, such as the implementation of the "two-invoice system," have adversely affected the company's sales and operations[111]. - The company’s revenue is primarily derived from sales in the Chinese market, which poses risks related to political and regulatory changes[111]. Future Outlook - The company plans to implement various business development strategies to mitigate operational risks and explore opportunities for expansion into other sectors and countries[20]. - The company aims to provide accurate, complete, and timely information to all stakeholders through established policies and procedures regarding insider information[76]. - The company is expected to manage its future working capital and financial needs despite the reported losses and uncertainties[176]. Shareholder Information - The company has adopted a dividend policy effective from January 1, 2020, which considers factors such as operating performance, cash flow, and financial condition[89]. - The board plans to recommend a dividend distribution of no less than 30% of the company's future distributable net profit in the foreseeable future[90]. - The company has a history of dividend distribution, but future dividends are not guaranteed and depend on the board's decisions and regulations[91]. - The company held one annual general meeting during the year ended December 31, 2020, providing shareholders the opportunity to communicate directly with the board[80].

Financial Performance - For the six months ended June 30, 2020, the company reported revenue of RMB 258,279,000, a decrease of 42.9% compared to RMB 452,188,000 for the same period in 2019[9] - The gross profit for the same period was RMB 6,857,000, down from RMB 32,032,000 in 2019, indicating a significant decline in profitability[9] - The company incurred a loss of RMB 8,823,000 for the six months ended June 30, 2020, compared to a profit of RMB 4,789,000 in the prior year, reflecting a negative turnaround[9] - Basic loss per share was reported at RMB (0.60), compared to earnings of RMB 0.32 per share in the same period of 2019[9] - The reported revenue for the six months ended June 30, 2020, was RMB 258,279 thousand, a decrease from RMB 452,298 thousand for the same period in 2019, representing a decline of approximately 42.9%[37] - The reported segment profit for the six months ended June 30, 2020, was RMB 6,857 thousand, down from RMB 32,021 thousand in the same period of 2019, indicating a decrease of about 78.6%[37] - Other income and gains for the six months ended June 30, 2020, totaled RMB 8,644 thousand, compared to RMB 11,535 thousand for the same period in 2019, reflecting a decline of approximately 25.8%[38] - The company incurred other losses of RMB 3,175 thousand for the six months ended June 30, 2020, compared to RMB 2,897 thousand for the same period in 2019, indicating an increase of about 9.6%[40] - Profit before tax turned from a profit of RMB 8.9 million for the six months ended June 30, 2019, to a loss of RMB 8.2 million for the six months ended June 30, 2020, representing a decrease of approximately 192.1%[116] - The group reported a net loss of RMB 8.8 million for the six months ended June 30, 2020, compared to a profit of RMB 4.8 million for the same period in 2019, a decrease of approximately 284.2%[118] Assets and Liabilities - Total assets as of June 30, 2020, were RMB 774,002,000, slightly up from RMB 771,892,000 at the end of 2019[13] - The company's cash and cash equivalents decreased to RMB 5,974,000 from RMB 16,125,000 at the end of 2019, indicating liquidity challenges[13] - The company’s inventory increased to RMB 15,448,000 from RMB 14,849,000, suggesting potential issues with stock turnover[13] - The accounts receivable rose to RMB 428,888,000 from RMB 373,740,000, indicating a growing collection risk[13] - The company's total non-current liabilities amounted to RMB 90,766 thousand, slightly up from RMB 88,310 thousand as of December 31, 2019[14] - The net asset value as of June 30, 2020, was RMB 683,236 thousand, a slight decrease from RMB 683,582 thousand at the end of 2019[14] - The company had a total equity attributable to shareholders of RMB 697,083 thousand, down from RMB 697,483 thousand at the end of 2019[14] - The total receivables as of June 30, 2020, were RMB 428,888,000, an increase of 14.8% from RMB 373,740,000 at the end of 2019[57] - The total accounts payable and other payables reached RMB 150,608,000, representing a significant increase of 34.5% from RMB 111,979,000 as of December 31, 2019[67] - The company reported a total of RMB 97,584,000 in corporate bonds payable as of June 30, 2020, up from RMB 91,014,000 at the end of 2019, indicating a growth of 7.5%[73] - The company has a total of RMB 32,195,000 in current liabilities due within one year as of June 30, 2020, compared to RMB 26,871,000 at the end of 2019[73] Cash Flow and Investments - The net cash generated from operating activities was RMB 26,297 thousand, compared to a net cash used of RMB 18,278 thousand in the same period last year[20] - The company reported a net cash outflow of RMB 10,145 thousand in cash and cash equivalents for the six months ended June 30, 2020[20] - The company recorded a net cash inflow from investing activities of RMB 12,899 thousand, a significant decrease from RMB 53,648 thousand in the previous year[20] - The company recognized revenue of RMB 568,000 from contract liabilities as of June 30, 2020, down 92.0% from RMB 7,103,000 at the end of 2019[72] - The company reported a significant increase in revenue, achieving a total of $X million for the quarter, representing a Y% growth year-over-year[150] - The company recorded a net cash inflow of RMB 4.912 million from the sale of a subsidiary, after accounting for cash and cash equivalents sold[106] Operational Efficiency - The cost of goods sold for the six months ended June 30, 2020, was RMB 251,422,000, a decrease of 40.2% compared to RMB 420,156,000 for the same period in 2019[42] - Total employee costs for the six months ended June 30, 2020, amounted to RMB 5,195,000, down 20.8% from RMB 6,561,000 in the previous year[42] - Selling and distribution expenses decreased by approximately 44.8% to RMB 3.6 million from RMB 6.5 million for the same period last year[111] - Administrative expenses decreased by approximately 40.7% to RMB 11.8 million from RMB 19.8 million, attributed to the absence of one-time acquisition-related costs[112] - The company has successfully reduced operational costs by G%, improving overall profitability margins[150] Corporate Governance - The company has two independent non-executive directors, which is below the minimum requirement of three as per listing rules[130] - The audit committee consists of two independent non-executive directors, with one possessing appropriate professional qualifications[133] - The company is reviewing and enhancing its corporate governance practices to ensure compliance with the corporate governance code[131] - The audit committee's main responsibilities include overseeing financial and accounting policies, internal controls, and risk management systems[132] Future Outlook - The company has not provided specific guidance for future performance, reflecting uncertainty in market conditions[8] - The company provided a positive outlook for the next quarter, projecting revenue growth of A% and an increase in user engagement metrics[150] - New product launches are expected to contribute an additional $B million in revenue, with a focus on expanding into new markets[150] - The company is considering strategic acquisitions to bolster its competitive position, with potential targets identified in the E sector[150] - Future guidance indicates a commitment to sustainable practices, with plans to invest H% of profits into environmentally friendly initiatives[150]

Annual Report 2019 年報 Pa Shun International Holdings Limited百信國際控股有限公司 Pa Shun International Holdings Limited 百信國際控股有限公司 (Incorporated in the Cayman Islands with limited liability) Stock Code : 574 Annual Report 2019 Pa Shun International Holdings Limited 百信國際控股有限公司 （於開曼群島註冊成立的有限公司） 股份代號 : 574 年報 2019 目錄 頁次 公司資料2 財務摘要4 財務概要5 管理層討論及分析6 企業管治報告 14 董事及高級管理層 27 董事會報告 31 獨立核數師報告 53 綜合損益表 63 綜合損益及其他全面收益表 64 綜合財務狀況表 65 綜合權益變動表 67 綜合現金流量表 68 綜合財務報表附註 71 1 百信國際控股有限公司 年報 2019 目錄 公司資料 2 百信國際控股有限公司 年報 2019 公司資料 | --- | ...

Annual Report 2018 年報 Pa S hun Intern atio n al H oldin gs Limite d | --- | --- | |------------------------------------------------------------------------------|----------------------------------------| | | | | | Pa Shun International Holdings Limited | | | | | 百信國際控股有限公司 | | | | | | (Incorporated in the Cayman Islands with limited liability) Stock Code : 574 | | 百 信 國 際 控 股 有 限 公 司 2018 Annual Report Pa Shun International Holdings Limited 百信國際控股有限公司 （於開曼群島註冊成立的有限公司） 股份代號 : 574 2018 年報 REM IPSUM DOLOR olor ...